BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $4,274,098 | +7.0% | 83,400 | +13.0% | 1.15% | -3.7% |
| Q3 2022 | $3,995,000 | +6.4% | 73,800 | +26.8% | 1.20% | +9.6% |
| Q2 2022 | $3,755,000 | -11.6% | 58,208 | +6.2% | 1.09% | +5.0% |
| Q1 2022 | $4,250,000 | -3.3% | 54,808 | +7.0% | 1.04% | -14.0% |
| Q4 2021 | $4,396,000 | +14.3% | 51,208 | +7.1% | 1.21% | +1.0% |
| Q3 2021 | $3,845,000 | +384400.0% | 47,808 | +597500.0% | 1.20% | – |
| Q2 2021 | $1,000 | -100.0% | 8 | -100.0% | 0.00% | -100.0% |
| Q1 2021 | $3,822,000 | +8.7% | 45,315 | +3.5% | 1.39% | -3.3% |
| Q4 2020 | $3,515,000 | +16.5% | 43,800 | +16.8% | 1.44% | -9.6% |
| Q3 2020 | $3,016,000 | +0.7% | 37,500 | +7.8% | 1.59% | -6.5% |
| Q2 2020 | $2,996,000 | +37350.0% | 34,800 | +34700.0% | 1.70% | +33900.0% |
| Q1 2020 | $8,000 | -99.7% | 100 | -99.7% | 0.01% | -99.7% |
| Q2 2019 | $2,670,000 | -0.8% | 32,600 | -1.5% | 1.58% | -6.5% |
| Q1 2019 | $2,691,000 | +34.5% | 33,100 | +8.9% | 1.69% | +23.0% |
| Q4 2018 | $2,001,000 | +1625.0% | 30,400 | +1926.7% | 1.38% | +1710.5% |
| Q3 2018 | $116,000 | +4.5% | 1,500 | 0.0% | 0.08% | -2.6% |
| Q2 2018 | $111,000 | +13.3% | 1,500 | 0.0% | 0.08% | +6.8% |
| Q1 2018 | $98,000 | +1.0% | 1,500 | 0.0% | 0.07% | -2.7% |
| Q4 2017 | $97,000 | – | 1,500 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |